metastatic murine os cell line k7m2  (ATCC)

Journal: Molecular Therapy Oncology

Article Title: Trabectedin promotes oncolytic virus antitumor efficacy, viral gene expression, and immune effector function in models of bone sarcoma

doi: 10.1016/j.omton.2024.200886

Figure Lengend Snippet: Trabectedin improves oHSV antitumor efficacy with reproducibility in immunocompetent osteosarcoma mouse models The best response for each treated tumor through 28 days, the average tumor burden, spider plots, and individual body weights are shown for treated osteosarcoma models (A) K7M2 and (B) F420 in immunocompetent BALB/c and B6-albino mice, respectively. Body weight plots include mice that were excluded from the tumor burden analyses due to early non-tumor-related endpoints. PBS and oHSV (1.0 × 10 8 pfu) were given i.Tu. on days 0, 2, and 4. Trabectedin (0.15 mg/kg) was given i.v. on days 0 and 7. Statistical analyses of the disease control rates (CR + PR + SD) were performed using a pairwise Fisher’s exact test with p values adjusted using the Benjamini-Hochberg procedure; ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, ∗∗∗ p ≤ 0.001. Summarized data with error bars depict mean ± SEM.

Article Snippet: The A673 human Ewing sarcoma cell line (Cat# CCL-81), Vero green monkey kidney cell line (Cat# CRL-1598), and K7M2 mouse osteosarcoma cell line (Cat# CRL-2836) were purchased from the American Type Culture Collection (ATCC) (Manassas, VA).

Techniques: Control

Journal: Molecular Therapy Oncology

Article Title: Trabectedin promotes oncolytic virus antitumor efficacy, viral gene expression, and immune effector function in models of bone sarcoma

doi: 10.1016/j.omton.2024.200886

Figure Lengend Snippet: Trabectedin reduces immune suppression and enhances effector cell activation to synergize with oHSV (A) scRNA-seq UMAP plot depicts the treated K7M2 tumor microenvironments. Datasets from all treatment groups were merged with no need for batch correction. (B) Bar plot displays the normalized enrichment score (NES) of the significant KEGG pathways from gene set enrichment analysis in NK and CD8 T cells from the tumor microenvironment. (C) FACS of tumor-infiltrating immune cells showed decreased immunosuppressive cells and increased activated T cells post-treatment. The p values calculated via one-way ANOVA with Dunnett’s multiple comparisons test are shown (wherein each treatment cohort was compared with the combination cohort). Error bars depict mean ± SEM. (D) Violin plots show increased cytotoxic gene expression in all NK and T cells of combination-treated K7M2 (arrow indicates control for comparison, percent change = 100∗(2 log2FC -1)). All treatment comparisons with a percent change value over 20% were statistically significant with p -adjusted ≤ 0.01. PBS and oHSV (1.0 × 10 8 pfu) were given i.Tu. on days 0 and 2. Trabectedin (0.15 mg/kg) was given i.v. on day 0. scRNA-seq samples were collected on day 3. Flow cytometry samples were collected on day 7.

Article Snippet: The A673 human Ewing sarcoma cell line (Cat# CCL-81), Vero green monkey kidney cell line (Cat# CRL-1598), and K7M2 mouse osteosarcoma cell line (Cat# CRL-2836) were purchased from the American Type Culture Collection (ATCC) (Manassas, VA).

Techniques: Activation Assay, Gene Expression, Control, Comparison, Flow Cytometry

Journal: Molecular Therapy Oncology

Article Title: Trabectedin promotes oncolytic virus antitumor efficacy, viral gene expression, and immune effector function in models of bone sarcoma

doi: 10.1016/j.omton.2024.200886

Figure Lengend Snippet: Combination efficacy in immunocompetent osteosarcoma models results from augmentation of antitumor NK and T cell responses The best response for each treated tumor through 28 days, the average tumor burden, and spider plots tracking individual tumor volumes over the full study period are displayed for (A) K7M2 tumor-bearing nude mice (lack T and B cells), (B) K7M2-bearing BALB/c mice treated with antibody-mediated CD4 and CD8 T cell depletion (given i.v. on days 0, 4, 8, 12, 16, 20, 24, and 28), (C) K7M2-bearing BALB/c mice treated with anti-asialo NK cell depletion (given i.v. on days 0, 7, 14, and 21). PBS and oHSV (1.0 × 10 8 pfu) were given i.Tu. on days 0, 2, and 4. Trabectedin (0.15 mg/kg) was given i.v. on days 0 and 7. Statistical analyses of the disease control rates (CR + PR + SD) were performed using a pairwise Fisher’s exact test with p values adjusted using the Benjamini-Hochberg procedure; ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, ∗∗∗ p ≤ 0.001. Summarized data with error bars depict mean ± SEM.

Article Snippet: The A673 human Ewing sarcoma cell line (Cat# CCL-81), Vero green monkey kidney cell line (Cat# CRL-1598), and K7M2 mouse osteosarcoma cell line (Cat# CRL-2836) were purchased from the American Type Culture Collection (ATCC) (Manassas, VA).

Techniques: Control